Endocrinol Metab.  2017 Dec;32(4):422-425. 10.3803/EnM.2017.32.4.422.

Decreasing Lean Body Mass with Age: Challenges and Opportunities for Novel Therapies

• Boutari C
• Mantzoros

• KMID: 2406185
• DOI: http://doi.org/10.3803/EnM.2017.32.4.422

Abstract

No abstract available.

MeSH Terms

Body Composition
Body Mass Index
Myostatin
Adiposity
Obesity
Muscle, Skeletal
Muscular Diseases

Reference

1. Kyle UG, Genton L, Hans D, Karsegard L, Slosman DO, Pichard C. Age-related differences in fat-free mass, skeletal muscle, body cell mass and fat mass between 18 and 94 years. Eur J Clin Nutr. 2001; 55:663–672.

2. Liu CK, Leng X, Hsu FC, Kritchevsky SB, Ding J, Earnest CP, et al. The impact of sarcopenia on a physical activity intervention: the Lifestyle Interventions and Independence for Elders Pilot Study (LIFE-P). J Nutr Health Aging. 2014; 18:59–64.

3. Kim SK, Kwon YH, Cho JH, Lee DY, Park SE, Oh HG, et al. Changes in body composition according to age and sex among young non-diabetic Korean adults: the Kangbuk Samsung Health Study. Endocrinol Metab. 2017; 32:442–450.

4. Roshanravan B, Patel KV, Fried LF, Robinson-Cohen C, de Boer IH, Harris T, et al. Association of muscle endurance, fatigability, and strength with functional limitation and mortality in the health aging and body composition study. J Gerontol A Biol Sci Med Sci. 2017; 72:284–291.

5. Johnson ML, Robinson MM, Nair KS. Skeletal muscle aging and the mitochondrion. Trends Endocrinol Metab. 2013; 24:247–256.

6. Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2010; 1:9–21.

7. Abbatecola AM, Paolisso G, Fattoretti P, Evans WJ, Fiore V, Dicioccio L, et al. Discovering pathways of sarcopenia in older adults: a role for insulin resistance on mitochondria dysfunction. J Nutr Health Aging. 2011; 15:890–895.

8. Guillet C, Zangarelli A, Gachon P, Morio B, Giraudet C, Rousset P, et al. Whole body protein breakdown is less inhibited by insulin, but still responsive to amino acid, in nondiabetic elderly subjects. J Clin Endocrinol Metab. 2004; 89:6017–6024.

9. Morley JE, Baumgartner RN. Cytokine-related aging process. J Gerontol A Biol Sci Med Sci. 2004; 59:M924–M929.

10. Lang CH, Frost RA, Nairn AC, MacLean DA, Vary TC. TNF-alpha impairs heart and skeletal muscle protein synthesis by altering translation initiation. Am J Physiol Endocrinol Metab. 2002; 282:E336–E347.

11. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006; 119:526.e9–526.e17.

12. Vamvini MT, Aronis KN, Chamberland JP, Mantzoros CS. Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males. J Clin Endocrinol Metab. 2011; 96:3416–3423.

13. Huang Z, Chen X, Chen D. Myostatin: a novel insight into its role in metabolism, signal pathways, and expression regulation. Cell Signal. 2011; 23:1441–1446.

14. Lee SJ. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol. 2004; 20:61–86.

15. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004; 350:2682–2688.

16. Yarasheski KE, Bhasin S, Sinha-Hikim I, Pak-Loduca J, Gonzalez-Cadavid NF. Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. J Nutr Health Aging. 2002; 6:343–348.

17. Mendivil CO. New IR biomarkers (myokines) in colombian people [Internet]. Bethesda: U.S. National Library of Medicine ClinicalTrials.gov;2017. cited 2017 Nov 15. Available from: http://clinicaltrials.gov/show/NCT03244449ClinicalTrials.gov.

18. Ratkevicius A, Joyson A, Selmer I, Dhanani T, Grierson C, Tommasi AM, et al. Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. J Gerontol A Biol Sci Med Sci. 2011; 66:620–626.

19. McPherron AC, Lee SJ. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest. 2002; 109:595–601.

20. Hittel DS, Berggren JR, Shearer J, Boyle K, Houmard JA. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes. 2009; 58:30–38.

21. Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013; 47:416–423.

22. Anastasilakis AD, Polyzos SA, Skouvaklidou EC, Kynigopoulos G, Saridakis ZG, Apostolou A, et al. Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans. Metabolism. 2016; 65:1459–1465.

23. Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A, Shilling C, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci U S A. 2008; 105:4318–4322.

24. Allen DL, Cleary AS, Speaker KJ, Lindsay SF, Uyenishi J, Reed JM, et al. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab. 2008; 294:E918–E927.

25. Mendias CL, Bakhurin KI, Faulkner JA. Tendons of myostatin-deficient mice are small, brittle, and hypocellular. Proc Natl Acad Sci U S A. 2008; 105:388–393.